Skip to main content

Advertisement

Table 4 Clinical risk factors for SSEs in two groups

From: Denosumab versus zoledronic acid for preventing symptomatic skeletal events in Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer: an outcome analyses with a mean follow-up of 3 years

  Denosumab ZA
Risk factors HR(95%CI) P –value HR(95%CI) P - value
Age (y) 0.003*   0.001*
≤60 1   1  
> 60 3.13(1.02–1.68)   4.72(2.36–7.17)  
Menopause age(y)   0.440   0.247
≤50 5.04(0.03–22.12)   5.04(0.03–22.12)  
> 50 1   1  
PHF   0.002*   0.005*
no 1   1  
yes 21.34(5.23–49.12)   36.75(2.39–74.32)  
FHF   0.037*   0.041*
no 1   1  
yes 6.79(1.10–11.65)   8.86(1.43–38.15)  
BMI(kg/m2)   0.793   0.219
≤19 3.76(0.66–31.32)   5.36(0.19–44.61)  
> 19 1   1  
  1. * Statistically significant values. SSEs: symptomatic skeletal events; ZA: zoledronic acid; PHF: personal history of fractures; FHF: family history of fractures; BMI: body mass index